A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J.
Cancer Discov. 2013 Oct;3(10):1142-55. doi: 10.1158/2159-8290.CD-13-0094. Epub 2013 Jul 18.
Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
Wappenschmidt B, Becker AA, Hauke J, Weber U, Engert S, Köhler J, Kast K, Arnold N, Rhiem K, Hahnen E, Meindl A, Schmutzler RK.
PLoS One. 2012;7(12):e50800. doi: 10.1371/journal.pone.0050800. Epub 2012 Dec 11.
Unclassified sex cord-stromal tumors of the ovary: a report of eight cases.
Simpson JL, Michael H, Roth LM.
Arch Pathol Lab Med. 1998 Jan;122(1):52-5.
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
Zhang S, Iyer S, Ran H, Dolgalev I, Gu S, Wei W, Foster CJR, Loomis CA, Olvera N, Dao F, Levine DA, Weinberg RA, Neel BG.
Cancer Discov. 2021 Feb;11(2):362-383. doi: 10.1158/2159-8290.CD-20-0455. Epub 2020 Nov 6.
Unclassified Mixed Germ Cell-Sex Cord-Stromal Tumor of the Ovary: An Unusual Case Report.
Saenz J, Rodriguez J, Beltran M, Medina M, Pareja R.
Cureus. 2020 Jul 23;12(7):e9350. doi: 10.7759/cureus.9350.
The Rare Gynecologic Sarcoma Study: Molecular and Clinicopathologic Results of A Project on 379 Uterine Sarcomas.
Dundr P, Hojný J, Dvořák J, Hájková N, Vránková R, Krkavcová E, Berjon A, Bizoń M, Bobiński M, Bouda J, Bui QH, Căpîlna ME, Ciccarone F, Flídrová M, Fröbe A, Grabowska K, Halaška MJ, Hausnerová J, Jedryka M, Laco J, Kalist V, Klát J, Kolníková G, Książek M, Marek R, Matěj R, Michal M, Michalová K, Ndukwe M, Němejcová K, Petróczy D, Piatnytska T, Póka R, Poprawski T, Ryś J, Sawicki W, Sharashenidze A, Stolnicu S, Stružinská I, Špůrková Z, Volodko N, Zapardiel I, Zikán M, Židlík V, Cibula D, Poncová R, Kendall Bártů M.
Lab Invest. 2025 May;105(5):104092. doi: 10.1016/j.labinv.2025.104092. Epub 2025 Feb 5.
Genetic testing and familial implications in breast-ovarian cancer families.
Oosterwijk JC, de Vries J, Mourits MJ, de Bock GH.
Maturitas. 2014 Aug;78(4):252-7. doi: 10.1016/j.maturitas.2014.05.002. Epub 2014 May 9.
Fluorescence in-situ hybridization assessment of spindle cell-rich testicular sex cord stromal tumors demonstrates multiple chromosomal gains across histologic subtypes.
Acosta AM, Fletcher CDM, Sholl LM, van Leenders GJ, Oliva E, Cornejo KM, Repetto F, Collins K, Idrees MT, Hirsch MS, Trpkov K, Ulbright TM, Bridge JA.
Hum Pathol. 2024 Nov;153:105652. doi: 10.1016/j.humpath.2024.105652. Epub 2024 Aug 30.
Understanding germ-line mutations in BRCA1.
Szabo CI, Worley T, Monteiro AN.
Cancer Biol Ther. 2004 Jun;3(6):515-20. doi: 10.4161/cbt.3.6.841. Epub 2004 Jun 1.
Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis.
Luo H, Li S, Zhao M, Sheng B, Zhu H, Zhu X.
Oncotarget. 2017 May 30;8(22):36845-36856. doi: 10.18632/oncotarget.15982.
